ClinicalTrials.Veeva

Menu

Dose Optimization of Caffeine for HIE

University of North Carolina (UNC) logo

University of North Carolina (UNC)

Status and phase

Enrolling
Phase 1

Conditions

Hypoxic-Ischemic Encephalopathy

Treatments

Drug: Caffeine citrate 30 mg/kg
Drug: Caffeine citrate 20 mg/kg

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT06448780
1K23HD111623-01 (U.S. NIH Grant/Contract)
24-0654

Details and patient eligibility

About

This is a phase Ib, open-label, dose-validating and safety study of caffeine in neonates with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia.

Full description

In a previous phase I trial (NCT03913221), the investigators characterized the pharmacokinetics (PK) of caffeine in the setting of HIE and therapeutic hypothermia using a population PK model. This is an open-label study of caffeine citrate in neonates with HIE to validate the population PK model and determine optimal dosing for HIE.

Enrollment

16 estimated patients

Sex

All

Ages

Under 24 hours old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Documented informed consent from parent or guardian
  • ≥ 36 weeks gestational age at birth
  • Receiving therapeutic hypothermia for a diagnosis of HIE
  • Intravenous (IV) access
  • Postnatal age < 24 hours

Exclusion criteria

  • Receiving > 1 anti-epileptic drug for seizures
  • Sustained (>4 hours) heart rate > 180 beats per minute
  • Known major congenital anomaly

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

16 participants in 2 patient groups

Lower loading dose (20 mg/kg)
Active Comparator group
Description:
Within 24 hours after delivery, participants will receive a loading dose of 20 mg/kg caffeine citrate IV.
Treatment:
Drug: Caffeine citrate 20 mg/kg
Higher loading dose (30 mg/kg)
Active Comparator group
Description:
Within 24 hours after delivery, participants will receive a loading dose of 30 mg/kg caffeine citrate IV.
Treatment:
Drug: Caffeine citrate 30 mg/kg

Trial contacts and locations

1

Loading...

Central trial contact

Wesley M Jackson, MD, MPH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems